Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
14
×
Tags
boston
14
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
14
×
biotech
clinical trials
san francisco blog main
deals
new york blog main
san francisco top stories
startups
fda
eli lilly
gene therapy
hepatitis b
investing
new york top stories
rna interference
roche
third rock ventures
vc
alexion pharmaceuticals
alnylam pharmaceuticals
atlas venture
avapritinib
blackstone group
blueprint medicines
boehringer ingelheim
cancer
crispr
david goldstein
depression
epilepsy
essential tremor
eventide asset management
genentech
indiana blog main
indiana top stories
What
medicines
14
×
drug
ago
drugs
genetic
new
research
therapeutics
diseases
gene
years
address
aims
approval
bio
biotech
biotechs
blueprint
cancer
dicerna
disease
emerged
fda
interference
ipo
ipos
long
muscle
pharma
pharmaceuticals
praxis
precision
ret
rna
roche
steer
step
stop
team
therapy
Language
unset
unknown
Current search:
photo
×
boston
×
" national top stories "
×
medicines
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
6 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”